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CLUSIONS: Classical test theory-based psychometric methods
generally supported the CES-D scale as an outcome measure of
depression after stroke. DIF on some items suggests that symp-
toms experienced in post-stroke depression may differ from
depression in the general population.
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Clinical trials often employ self-rated and interviewer-rated
instruments to assess the effectiveness of anxiolytic treatments.
Understanding potential differences in these scales and their psy-
chometric properties therefore is important for interpreting trial
results. OBJECTIVES: Identify and critique key methods used to
compare psychometric properties of self-versus interviewer-rated
instruments in clinical trials for patients with anxiety disorders.
METHODS: A literature review focusing on anxiety outcome
assessments used in clinical trials was conducted in Medline,
OLGA, and PsychINFO databases of articles published before
September 2003. This study included only articles that were pub-
lished in English and reported data from clinical trials with anx-
iolytic drugs. RESULTS: From the literature review, two
commonly used instruments included the self-rated Symptom
Checklist-90, and the interviewer-rated Hamilton Rating Scale
for Anxiety. Five methodological approaches were identiﬁed: 1)
precision of measurement: means and variances of instrument
scores; 2) construct validity: comparison of underlying con-
structs for each instrument using factor analysis; 3) internal 
consistency: homogeneity of items within the same domain of an
instrument; 4) instrument sensitivity: ability of the instrument to
detect treatment effect by differentiating control from treatment
groups or between groups of different disease states; and 5)
instrument responsiveness: ability of each instrument to detect
minimal clinically important changes within patients over time
(pre-and post-treatment phases) using distribution-based and
anchor-based approaches. Tests for statistical and clinical signif-
icances in score changes are discussed. For each of the ﬁve
approaches, suggested statistical methods and examples from the
literature are presented. CONCLUSIONS: The structured tax-
onomy developed in this study will help interpret clinical trial
results that use self-rated and interviewer-rated instruments, as
well as elucidate potential methods for developing and validat-
ing new instruments to assess the effectiveness of anxiolytic treat-
ments in trials.
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OBJECTIVES: Bipolar disorder, as well as some of the pharma-
cological agents used to treat it, often impairs patients’ ability to
function on a day-to-day basis. The goal of the present study was
to develop a sensitive, psychometrically sound self-report instru-
ment that would help to identify treatments effective in maxi-
mizing the functional status of bipolar patients. METHODS:
Through consultation with key opinion leaders, literature review,
and individual in-depth interviews with bipolar patients, the
team developed a questionnaire using 50 items to address the
following domains: cognitive functioning, sleep, role function-
ing, emotional functioning, energy/vitality, social functioning,
personal management, and sexual functioning. The draft ques-
tionnaire was then tested and revised through 2 iterative sets of
cognitive interviews with 19 additional patients in multiple loca-
tions. RESULTS: In general, the pretest participants deemed the
set of constructs addressed in the questionnaire to be both com-
prehensive and representative of their daily functioning. They
also reported that the ﬁnal set of items was easy to comprehend
and to ﬁll in, noting that the 7-point Likert-type response scale
seemed optimal; the points on the scale appeared to represent
the full spectrum of answer choices, yet participants could easily
distinguish between the options. Cognitive testing also resulted
in the elimination of 17 items, which were either deemed inessen-
tial to the measurement of functional status, applicable only to
a subset of patients (eg, family responsibilities), or too similar in
content to other items. CONCLUSIONS: The resulting ques-
tionnaire addresses all constructs considered central to the func-
tional status of patients with bipolar disorder, with 33 items that
are phrased to facilitate patient comprehension and completion.
A multisite, 600-patient validation study is currently under way
to evaluate the psychometric properties of this instrument.
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OBJECTIVES: The potential for antipsychotic-induced diabetes
is an important issue. Retrospective studies using large patient
databases have had conﬂicting ﬁndings regarding diabetes risks
associated with different antipsychotics. METHODS: Claims
data for thousands of psychosis patients treated or untreated
with antipsychotics were analyzed. Screening for preexisting dia-
betes, identiﬁcation of diabetes with prescription claims only,
and requirement of antipsychotic monotherapy provide better
control for confounding inﬂuences and represent a stronger
study design. Diabetes odds ratios for risperidone, olanzapine,
quetiapine, or conventional antipsychotics versus non-treatment
were estimated for all patients and for patients stratiﬁed by dose
levels. Logistic regression controlled for age, sex, type of 
psychosis, length of observation/treatment, preexisting excess
weight, and use of other drugs with diabetogenic effects.
RESULTS: Under a weaker study design, all of the antipsychotics
were associated with signiﬁcantly higher odds of diabetes rela-
tive to non-treatment. Odds ratios (95% conﬁdence intervals
[CI]) were: risperidone 1.388 (1.276–1.509), olanzapine 1.331
(1.224–1.446), quetiapine 1.394 (1.247–1.559), and conven-
tional antipsychotics 1.365 (1.238–1.503). Under a stronger
study design, relative odds for risperidone and quetiapine
declined, becoming statistically insigniﬁcant, whereas odds for
olanzapine and conventional antipsychotics increased. Odds
ratios (95% CI) were: risperidone 1.224 (0.962–1.562), olanza-
pine 1.858 (1.549–2.238), quetiapine 1.087 (0.742–1.612), and
conventional antipsychotics 1.755 (1.381–2.221). With quetiap-
ine, odds of diabetes were not signiﬁcantly increased at any dose
level relative to non-treatment. Odds were signiﬁcantly increased
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at all dose levels with conventional antipsychotics, at medium
and high doses with, olanzapine, and at high doses with risperi-
done. CONCLUSIONS: In database studies, estimated risks 
of diabetes among antipsychotics are affected by study design.
When a more reliable design was used, risks associated with que-
tiapine and risperidone were lower than those of olanzapine and
conventional antipsychotics and not signiﬁcantly different from
those in untreated patients.
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OBJECTIVES: Phototherapy is widely used for the treatment of
seasonal affective disorder (SAD). Evidence for its efﬁcacy comes
primarily from crossover trials in which patients received pho-
totherapy or a placebo treatment, and then crossed over to
receive the opposite treatment. METHODS: Our meta-analysis
of controlled trials of phototherapy found statistically signiﬁcant
heterogeneity among study results (Q = 20.39, p = 0.08). Study
design (parallel or crossover) and blinding both inﬂuenced the
magnitude of the reported effect. Unblinded, crossover studies
had signiﬁcantly larger treatment effects than blinded parallel
studies (p = 0.01). Three crossover studies reported data sepa-
rately for treatments before and after patients crossed over. In
these studies, treatment effects prior to the crossover were similar
to treatment effects observed in parallel trials (p = 0.36).
However, treatment effects from the second, post-crossover
period are signiﬁcantly greater than in parallel trials (p = 0.001).
RESULTS: Further examination of these trials showed that not
only were differences between treated and placebo patients sig-
niﬁcantly greater after the crossover than before (p = 0.04), but
depression ratings after active treatment were signiﬁcantly lower
among patients receiving active treatment after crossover than
among those receiving active treatment before crossover (p =
0.02). These differences persist when one examines number of
responders to therapy rather than raw depression ratings (p =
0.03 or p = 0.002, depending on the deﬁnition of “responder”
used. Moreover, placebo responses are larger when patients
receive placebo treatment before crossover compared to after
crossover, although this difference is statistically signiﬁcant 
only for one deﬁnition of “responder” (p = 0.04). CONCLU-
SION: These ordering effects may be the result of loss of blind-
ing after crossover. These results suggest that proper patient
blinding is essential in the evaluation of interventions for affec-
tive or other psychological disorders. Crossover studies, which
because patients are exposed to both treatments cannot be
blinded, are inappropriate for investigating the efﬁcacy of such
treatments.
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OBJECTIVES: Depression is common, affecting approximately
9.5% of American adults each year. Depression tends to be
under-diagnosed and under-treated in the primary care setting.
Due to numerous obstacles, primary care physicians fail to diag-
nose depression in up to 50% of cases. The tendency to priori-
tize medical problems in the primary care setting may lead to
failure to detect depression in patients with unexplained somatic
symptoms. Assessment tools may help providers identify cases 
of depression within the constraints of a typical ofﬁce practice
and can provide signiﬁcant value for patients, providers, and
managed care organizations. METHODS: The study was
designed to assess the impact of electronic messaging on the 
identiﬁcation and treatment of depression in patients with low
back pain. Electronic-prescribers received a message after enter-
ing an ICD-9 code for low back pain. The message brieﬂy
describes the relationship between depression and pain, and
offers the option to view a depression screener and a summary
of treatment guidelines. Examining drugs prescribed for patients
with low back pain assessed the intervention. Physician
encounter data were assessed before and after messaging imple-
mentation. RESULTS: Physicians that received the electronic
messages were more likely to identify depression in patients with
low back pain. An increase in the proportion of patients with
low back pain prescribed antidepressants may indicate that the
electronic messages assisted physicians in the identiﬁcation and
treatment of depression in these patients. CONCLUSIONS: Elec-
tronic messaging at the point of care appears to be an effective
method to offer information to physicians at the time the infor-
mation is needed.
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OBJECTIVES: To validate models predicting the likelihood of
treatment response to olanzapine and risperidone among schiz-
ophrenics participating in clinical trials. METHODS: Data from
two randomized, double-blind clinical trials comparing olanza-
pine to risperidone were pooled for analysis. Separate models
were developed for subjects randomized to olanzapine or risperi-
done. Baseline independent variables present in both trials were
included as predictors of subsequent treatment response. Treat-
ment response was deﬁned as >20% reduction in scale total from
the Positive and Negative Syndrome Scale (PANSS) at 8 weeks.
Each treatment group was partitioned at random into 70% for
model development (training), and 30% for model validation.
Classiﬁcation trees were used to determine variables of impor-
tance in discriminating responders from non-responders among
patients that had been randomized to risperidone and olanzap-
ine, respectively. These variables were then used to build logis-
tic regression models predicting treatment response for each
therapy. The resulting logistic regression models were then vali-
dated on the 30% of cases set aside for this purpose. RESULTS:
Classiﬁcation trees identiﬁed different variables as important in
discriminating responders from non-responders for olanzapine
than for risperidone recipients. The resulting logistic model for
olanzapine response correctly classiﬁed 64.9% of cases’ response
status, for a Kappa of .29 (“fair” agreement in predicted v.
observed response, p < 0.05) in the training data, and.37 (p <
0.05) in the validation data. The risperidone model resulted in
69.2% classiﬁcation agreement, for a Kappa of 0.39 (“fair”
agreement, p < .05) in the training data and .28 (p < 0.05) in the
validation data. CONCLUSIONS: Our ﬁndings support the fea-
sibility of estimating the likelihood of response to antipsychotic
medications using models built from clinical trial data, and that
different baseline characteristics contribute to response to dif-
ferent agents. Further study is needed to determine the implica-
tions and value of such predictions, and to further assess
generalizability outside of trial settings.
